DK3424532T3 - Influenzavirus-antistofsammensætninger - Google Patents
Influenzavirus-antistofsammensætninger Download PDFInfo
- Publication number
- DK3424532T3 DK3424532T3 DK18183550.5T DK18183550T DK3424532T3 DK 3424532 T3 DK3424532 T3 DK 3424532T3 DK 18183550 T DK18183550 T DK 18183550T DK 3424532 T3 DK3424532 T3 DK 3424532T3
- Authority
- DK
- Denmark
- Prior art keywords
- influenza virus
- antibody compositions
- virus antibody
- compositions
- influenza
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1115214.7A GB201115214D0 (en) | 2011-09-02 | 2011-09-02 | Influenza virus antibody compositions |
| EP12756552.1A EP2750708B1 (en) | 2011-09-02 | 2012-09-03 | Influenza virus antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3424532T3 true DK3424532T3 (da) | 2021-04-12 |
Family
ID=44882148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18183550.5T DK3424532T3 (da) | 2011-09-02 | 2012-09-03 | Influenzavirus-antistofsammensætninger |
| DK12756552.1T DK2750708T3 (da) | 2011-09-02 | 2012-09-03 | Influenzavirus-antistofsammensætninger |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12756552.1T DK2750708T3 (da) | 2011-09-02 | 2012-09-03 | Influenzavirus-antistofsammensætninger |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9771415B2 (da) |
| EP (2) | EP3424532B1 (da) |
| JP (1) | JP6279469B2 (da) |
| CN (1) | CN104053453B (da) |
| AU (1) | AU2012300592B2 (da) |
| BR (1) | BR112014004860B1 (da) |
| CA (1) | CA2847263C (da) |
| DK (2) | DK3424532T3 (da) |
| ES (2) | ES2864711T3 (da) |
| GB (1) | GB201115214D0 (da) |
| WO (1) | WO2013030604A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| WO2014161483A1 (zh) | 2013-04-02 | 2014-10-09 | 厦门大学 | 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体 |
| US10000556B2 (en) | 2013-05-09 | 2018-06-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use |
| US20160200799A1 (en) * | 2013-08-23 | 2016-07-14 | Fujita Health University | Anti-influenza virus neutralizing antibody |
| CN103804493B (zh) * | 2014-01-27 | 2015-12-30 | 南通伊仕生物技术股份有限公司 | 针对甲型流感病毒h1n1的重链抗体vhh及其应用 |
| CN103936852B (zh) * | 2014-05-14 | 2016-08-17 | 南通伊仕生物技术股份有限公司 | 特异性针对甲型h3n2流感病毒的纳米抗体及其在诊断中的应用 |
| US10732180B2 (en) | 2014-06-04 | 2020-08-04 | Indevr, Inc. | Universal capture array for multiplexed subtype-specific quantification and stability determination of influenza proteins |
| EP3253411A1 (en) | 2015-02-05 | 2017-12-13 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
| JP2017036258A (ja) * | 2015-08-07 | 2017-02-16 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
| US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CA3015347A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| JP6868763B2 (ja) * | 2016-04-01 | 2021-05-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
| JP6931765B2 (ja) * | 2016-06-01 | 2021-09-08 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| JP2018058812A (ja) * | 2016-06-01 | 2018-04-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| US9988435B2 (en) | 2016-06-01 | 2018-06-05 | Panasonic Intellectual Property Management Co., Ltd. | Composite comprising antibody capable of binding to intranuclear protein of influenza virus |
| US9988436B2 (en) | 2016-06-01 | 2018-06-05 | Panasonic Intellectual Property Management Co., Ltd. | Composite comprising antibody capable of binding to intranuclear protein of influenza virus |
| JP2020137414A (ja) * | 2017-06-26 | 2020-09-03 | 国立研究開発法人理化学研究所 | 変異ｖｈｈ抗体及びその製造方法 |
| JP2019011297A (ja) | 2017-06-30 | 2019-01-24 | パナソニックＩｐマネジメント株式会社 | ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| WO2019054198A1 (ja) * | 2017-09-12 | 2019-03-21 | パナソニックＩｐマネジメント株式会社 | インフルエンザウイルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| JP7178608B2 (ja) | 2017-09-12 | 2022-11-28 | パナソニックＩｐマネジメント株式会社 | インフルエンザウイルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| JP7065338B2 (ja) | 2017-09-12 | 2022-05-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウイルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| JP7162190B2 (ja) | 2018-07-17 | 2022-10-28 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| JP7178623B2 (ja) * | 2018-07-17 | 2022-11-28 | パナソニックＩｐマネジメント株式会社 | 検出装置 |
| JP7308477B2 (ja) | 2019-03-11 | 2023-07-14 | パナソニックＩｐマネジメント株式会社 | 抗体、複合体、それを用いた検出装置及び検出方法 |
| JP2022521819A (ja) | 2019-03-25 | 2022-04-12 | ビステラ， インコーポレイテッド | インフルエンザを処置および予防するための組成物および方法 |
| EP3799881A1 (en) * | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
| WO2023112965A1 (ja) * | 2021-12-15 | 2023-06-22 | 学校法人帝京平成大学 | Ｖｈｈ抗体 |
| CN115043936B (zh) * | 2022-03-31 | 2023-06-27 | 深圳市人民医院 | 靶向新冠病毒的纳米抗体及其制备方法和应用 |
| CN114805608B (zh) * | 2022-05-20 | 2023-05-19 | 青岛农业大学 | 一种基于自组装铁蛋白抗甲型h1n1亚型流感病毒的纳米颗粒及其制备方法和应用 |
| CN117720649B (zh) * | 2023-03-10 | 2025-12-05 | 福建圣维生物科技有限公司 | 抗h9亚型禽流感病毒的纳米抗体及其表达工程菌株与制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5973698A (ja) | 1982-10-20 | 1984-04-25 | Nichiwa Sangyo Kk | 単管脱圧型分配弁による高所配管のシステム |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| GB0522460D0 (en) * | 2005-11-03 | 2005-12-14 | Prendergast Patrick T | Composition and method for the treatment of avian influenza |
| EP2059532B1 (en) | 2006-09-07 | 2012-12-26 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| US9662383B2 (en) * | 2007-03-26 | 2017-05-30 | University Of Massachusetts | Compositions and methods for increasing immunogenicity of glycoprotein vaccines |
| FR2921928B1 (fr) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| WO2009079793A1 (en) | 2007-12-21 | 2009-07-02 | National Research Council Of Canada | Non-aggregating human vh domains |
| US20120128684A1 (en) * | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
| AU2010205627B2 (en) * | 2009-01-14 | 2015-04-02 | Ablynx Nv | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20120128671A1 (en) * | 2009-05-13 | 2012-05-24 | Lawrence Horowitz | Neutralizing molecules to influenza viruses |
| US8673314B2 (en) * | 2009-05-26 | 2014-03-18 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
-
2011
- 2011-09-02 GB GBGB1115214.7A patent/GB201115214D0/en not_active Ceased
-
2012
- 2012-09-03 EP EP18183550.5A patent/EP3424532B1/en active Active
- 2012-09-03 WO PCT/GB2012/052164 patent/WO2013030604A1/en not_active Ceased
- 2012-09-03 DK DK18183550.5T patent/DK3424532T3/da active
- 2012-09-03 DK DK12756552.1T patent/DK2750708T3/da active
- 2012-09-03 ES ES18183550T patent/ES2864711T3/es active Active
- 2012-09-03 CN CN201280053282.0A patent/CN104053453B/zh active Active
- 2012-09-03 BR BR112014004860-6A patent/BR112014004860B1/pt active IP Right Grant
- 2012-09-03 ES ES12756552T patent/ES2698899T3/es active Active
- 2012-09-03 JP JP2014527742A patent/JP6279469B2/ja active Active
- 2012-09-03 AU AU2012300592A patent/AU2012300592B2/en active Active
- 2012-09-03 US US14/342,376 patent/US9771415B2/en active Active
- 2012-09-03 CA CA2847263A patent/CA2847263C/en active Active
- 2012-09-03 EP EP12756552.1A patent/EP2750708B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104053453A (zh) | 2014-09-17 |
| US20140302063A1 (en) | 2014-10-09 |
| EP3424532A1 (en) | 2019-01-09 |
| US9771415B2 (en) | 2017-09-26 |
| ES2864711T3 (es) | 2021-10-14 |
| GB201115214D0 (en) | 2011-10-19 |
| EP2750708A1 (en) | 2014-07-09 |
| EP2750708B1 (en) | 2018-08-22 |
| ES2698899T3 (es) | 2019-02-06 |
| JP6279469B2 (ja) | 2018-02-14 |
| CA2847263C (en) | 2021-04-20 |
| EP3424532B1 (en) | 2021-01-06 |
| CN104053453B (zh) | 2019-03-29 |
| BR112014004860B1 (pt) | 2022-09-20 |
| DK2750708T3 (da) | 2018-12-10 |
| JP2014527065A (ja) | 2014-10-09 |
| BR112014004860A2 (pt) | 2019-07-02 |
| AU2012300592A1 (en) | 2014-03-20 |
| AU2012300592B2 (en) | 2017-09-28 |
| WO2013030604A1 (en) | 2013-03-07 |
| CA2847263A1 (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3424532T3 (da) | Influenzavirus-antistofsammensætninger | |
| HUS2300021I1 (hu) | Anti-IL-36R antitestek | |
| IL232053A0 (en) | Antibody formulations | |
| LT2791160T (lt) | Modifikuotos mrnr sudėtys | |
| BR112014003052A2 (pt) | composições farmacêuticas | |
| DK3447131T3 (da) | Influenza a-virusmutanter | |
| HUE036663T2 (hu) | Készítmény anti-alfa4béta7 antitesthez | |
| HUE036664T2 (hu) | Készítmény anti-alfa4béta7 antitesthez | |
| BR112013017183A2 (pt) | composições de bepostatina | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| CO6950492A2 (es) | Composiciones plaguicidas estables | |
| BR112013022112A2 (pt) | composição | |
| BR112013022102A2 (pt) | composição | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| BR112014004395A2 (pt) | composição | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| IL227789A0 (en) | Hepatitis c virus inhibitors | |
| CO6930368A2 (es) | Composiciones de yodo-povidona estable | |
| IL229270A0 (en) | Hepatitis c virus inhibitors | |
| HUE040370T2 (hu) | Gyógyszerkészítmények | |
| BR112013033808A2 (pt) | composição | |
| BR112014005756A2 (pt) | vacina | |
| FI11374U1 (fi) | Bensiinikoostumukset |